Concepedia

Xiaoyu Zhu

XZ

Statistics

Publications

71

Citations

4K

H-Index

30

Active since

1997

Affiliations

Jiangsu Hengrui Medicine (China)(Current)

Anhui Provincial Hospital

University of Science and Technology of China

Peking University

Anhui Medical University

Xiaoyu Zhu is an author at Jiangsu Hengrui Medicine (China) specializing in medicine, pharmacology, and oncology.

ORCID

Publications per year

1997–2025

71

Publications

71

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 393 citations

, , +16

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 345 citations

, , +17

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang, Yin Liu, Yi Xiao et al. · Cell Research · 2020 · 314 citations · Full text

, , +16

Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Caicun Zhou, Xingya Li, Qiming Wang et al. · Journal of Clinical Oncology · 2020 · 206 citations

, , +16

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 169 citations

, , +12

1–5 of 71